Despite the slight impact of rogaratinib monotherapy on tumor cells with FGFR3 mutation when baseline parameters are used, our model simulations show that its combination with anti-PD-L1 therapy increases the effect size of the anti-PD-L1 therapy on tumor cells with the FGFR3 mutation. This evidence concerns the gene CD274 and neoplasm.